Finding the Right Antipsychotic Dose After Cannabis-Induced Psychosis
A nationwide Swedish study found that moderate antipsychotic doses were most effective at preventing psychotic relapse after cannabis-induced psychosis — higher doses didn't add benefit and likely increased side effects.
Quick Facts
What This Study Found
Using linked Swedish health registers, researchers identified all individuals with a first diagnosis of cannabis-induced psychosis and conducted a dose-response analysis of oral antipsychotic medications.
The analysis modeled antipsychotic exposure as time-dependent across three dose categories (low: <0.6 DDD, moderate: 0.6–<1.4 DDD, high: ≥1.4 DDD) using within-individual comparisons — meaning each person served as their own control across different exposure periods.
The primary outcome was hospitalization for any psychotic episode (schizophrenia-spectrum disorder or substance-induced psychosis). The results showed a dose-response curve that plateaued at moderate doses: low doses provided some protection, moderate doses were most effective, and high doses did not add further benefit.
The within-individual design is particularly strong because it eliminates confounding from differences between patients (genetics, severity, comorbidities) — it only compares how the same person fares at different dose levels.
Key Numbers
Three dose categories: <0.6 DDD (low), 0.6–<1.4 DDD (moderate), ≥1.4 DDD (high). Medications analyzed: aripiprazole, clozapine, risperidone, olanzapine, quetiapine, polytherapy, and others. Outcome: hospitalization for schizophrenia-spectrum or substance-induced psychosis. Moderate doses showed optimal protection; high doses showed no additional benefit.
How They Did This
Nationwide cohort study using linked Swedish administrative and healthcare registers. All first diagnoses of cannabis-induced psychosis (ICD-10 F12.5) identified. Antipsychotic exposure modeled as time-dependent using validated PRE2DUP method. Dose-response analyzed across three DDD categories. Within-individual stratified Cox regression. Primary outcome: hospitalization for psychotic episode.
Why This Research Matters
Cannabis-induced psychosis carries a high conversion rate to chronic psychotic illness (RTHC-00251 found ~34% convert to schizophrenia). Antipsychotics can prevent relapse, but they carry dose-related side effects including weight gain, metabolic syndrome, and movement disorders. This study provides the first real-world dose optimization data, suggesting clinicians can achieve maximum benefit at moderate doses without the added burden of high-dose treatment.
The Bigger Picture
This connects directly to the psychosis conversion meta-analysis (RTHC-00251) by addressing what to do about that ~34% conversion rate. If moderate-dose antipsychotics can reduce relapse without the full side-effect burden of high doses, that changes the risk-benefit calculation for treating cannabis-induced psychosis — potentially making clinicians and patients more willing to use preventive medication during the critical post-episode period.
What This Study Doesn't Tell Us
Register-based study — medication exposure is estimated from dispensing records, not confirmed adherence. Cannabis use during follow-up was not measured and may confound results. The Swedish healthcare system may not generalize to other settings. Within-individual design requires that patients contribute periods at different dose levels, which may introduce selection effects.
Questions This Raises
- ?Does the optimal dose differ by specific antipsychotic (e.g., aripiprazole vs. olanzapine)?
- ?How long should antipsychotic treatment continue after cannabis-induced psychosis?
- ?Would combining moderate-dose antipsychotics with cannabis cessation support further reduce relapse rates?
Trust & Context
- Key Stat:
- Evidence Grade:
- Nationwide cohort study with within-individual design — one of the strongest observational designs available, leveraging Sweden's comprehensive health registers.
- Study Age:
- Published in 2026 using Swedish register data, providing real-world evidence on antipsychotic dosing that complements clinical trial data.
- Original Title:
- Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study.
- Published In:
- Psychiatry research, 358, 116966 (2026) — Psychiatry Research is a reputable journal focusing on mental health and psychiatric studies.
- Authors:
- Mustonen, Antti(2), Niemelä, Solja(4), Denissoff, Alexander(2), Forti, Marta Di, Tanskanen, Antti, Mittendorfer-Rutz, Ellenor, Tiihonen, Jari, Taipale, Heidi
- Database ID:
- RTHC-08514
Evidence Hierarchy
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-08514APA
Mustonen, Antti; Niemelä, Solja; Denissoff, Alexander; Forti, Marta Di; Tanskanen, Antti; Mittendorfer-Rutz, Ellenor; Tiihonen, Jari; Taipale, Heidi. (2026). Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study.. Psychiatry research, 358, 116966. https://doi.org/10.1016/j.psychres.2026.116966
MLA
Mustonen, Antti, et al. "Optimizing antipsychotic dosing for relapse prevention in cannabis-induced psychosis: A nationwide cohort study.." Psychiatry research, 2026. https://doi.org/10.1016/j.psychres.2026.116966
RethinkTHC
RethinkTHC Research Database. "Optimizing antipsychotic dosing for relapse prevention in ca..." RTHC-08514. Retrieved from https://rethinkthc.com/research/mustonen-2026-optimizing-antipsychotic-dosing-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.